Cited by 463Acute Myeloid Leukemia ResearchCancer-related Molecular PathwaysRetinoids in leukemia and cellular processes

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, Martin, Saft, Leonie, Smith, Alexander, Kulasekararaj, Austin, Pomplun, Sabine, Göhring, Gudrun, Hedlund, Anette, Hast, Robert, Schlegelberger, Brigitte, Porwit, Anna, Hellström-Lindberg, Eva, Mufti, Ghulam J.·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2010.31.8576

Open this paper in CoChat — free account

Abstract

Purpose: To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression. Patients and Methods: Pre- and postprogression bone marrow (BM) samples from 55 consecutive patients with International Prognostic Scoring System low risk (n = 32) or intermediate-1 risk (n = 23) were studied by next-generation sequencing of TP53. IHC for p53 was performed on 148 sequential BM samples. Results: TP53 mutations with a median clone size of 11% (range, 1% to 54%) were detected in 10 patients (18%) already at an early phase of the disease. Mutations were equally common in low-risk and intermediate-1–risk patients and were associated with evolution to acute myeloid leukemia (5 of 10 v 7 of 45; P = .045). Nine of 10 patients carrying mutations showed more than 2% BM progenitors with strong p53 staining. The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). Conclusion: By using sensitive deep-sequencing technology, we demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q). Importantly, mutations were present years before disease progression and were associated with an increased risk of leukemic evolution. TP53 mutations could not be predicted by common clinical features but were associated with p53 overexpression. Our findings indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.

Integrity signals

Registry

Crossref · 10.1200/jco.2010.31.8576

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citation
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
Malcovati, L., Germing, U., Kuendgen, A., Porta, M. G. D., Pascutto, C., Invernizzi, R., Giagounidis, A. A. N., Hildebrandt, B., BERNASCONI, P. P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,029
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome
Barlow, J. L., Drynan, L. F., Hewett, D. R., Holmes, L. R., Lorenzo-Abalde, S., Lane, A. L., Jolin, H. E., Pannell, R., Middleton, A. J., Wong, S. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2063 · Cited by 349
Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua, R. A., Guinn, B., Al-Sabah, A., Smith, M. T., Taylor, C., Pettersson, T., Ridge, S. A., Carter, G., White, D., Oscier, D. G., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401044 · Cited by 213
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
Giagounidis, A. A. N., Germing, U., Haase, S. P., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H. P. J., Aivado, M. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403189 · Cited by 210
Self-citation
Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Laï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197
Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123

Show all 33 references

Research works printed but not linked: 9

Preudhomme C, 1994, Leukemia, 8, 2241
Lai JL, 1995, Leukemia, 9, 370
Kitagawa M, 1994, Am J Pathol, 145, 338
Ludwig L, 1992, Leukemia, 6, 1302
Fidler C, 2004, Haematologica, 89, 865
Fenaux P, 1990, Nouv Rev Fr Hematol, 32, 341
Lepelley P, 1994, Leukemia, 8, 1342
Ramos F, 2002, Haematologica, 87, 381
Orazi A, 1996, Mod Pathol, 9, 48

Sorted by citations

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Rücker, F. G., Schlenk, R. F., Bullinger, L., Käyser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2011) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 694
Self-citation
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Malcovati, L., Hellström‐Lindberg, E., Bowen, D., Adès, L., Čermák, J., del Cañizo, C., Porta, M. G. D., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 682
Self-citation
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Self-citation
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J. R., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 661
Myelodysplastic Syndromes
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 428
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 403
Myelodysplastic syndromes
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 418
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Kar, S. A., Jerez, A., Przychodzen, B. P., Bupathi, M., Guinta, K. M., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 387
Genetics of MDS
Ogawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 382
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 352
The genetic basis of myelodysplasia and its clinical relevance
Cazzola, M., Porta, M. G. D., & Malcovati, L. (2013) · Blood · doi:10.1182/blood-2013-09-381665 · Cited by 355
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll, P. S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D. C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.036 · Cited by 333
Self-citation
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
Walter, M. J., Shen, D., Shao, J., Ding, L., White, B. S., Kandoth, C., Miller, C. A., Niu, B., McLellan, M. D., Dees, N. D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.58 · Cited by 284
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G. S., Brown, J., Lau, A., Pratt, G., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 288
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259
Self-citation
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Porta, M. G. D., Gallì, A., Bacigalupo, A. P., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., Lint, M. T. V., Pioltelli, P. E., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 261
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia
Malcovati, L., Papaemmanuil, E., Ambaglio, I., Elena, C., Gallì, A., Porta, M. G. D., Travaglino, E., Pietra, D., Pascutto, C., Ubezio, M., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560227 · Cited by 259
Diagnosis and classification of hematologic malignancies on the basis of genetics
Taylor, J., Xiao, W., & Abdel-Wahab, O. I. (2017) · Blood · doi:10.1182/blood-2017-02-734541 · Cited by 260
TP 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250
Self-citation
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., Fasan, A., & Haferlach, C. (2016) · Leukemia · doi:10.1038/leu.2016.263 · Cited by 256
Treatment of MDS
Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 244
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231
Self-citation
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 241
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 212
Myelodysplastic syndromes: Contemporary review and how we treat
Gangat, N., Patnaik, M. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24253 · Cited by 200
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 192
Role of ribosomal protein mutations in tumor development (Review)
Goudarzi, K. M., & Lindström, M. S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3387 · Cited by 182
Genetics of progression from MDS to secondary leukemia
Menssen, A. J., & Walter, M. J. (2020) · Blood · doi:10.1182/blood.2019000942 · Cited by 182
Recent developments in myelodysplastic syndromes
Bejar, R. L., & Steensma, D. P. (2014) · Blood · doi:10.1182/blood-2014-04-522136 · Cited by 179
TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P., Haase, D. T., Sanz, G. F., Santini, V., & Buske, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu180 · Cited by 174
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Mouhieddine, T. H., Sperling, A. S., Redd, R. A., Park, J., Leventhal, M. J., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16805-5 · Cited by 176
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
Fenaux, P., Haase, D. T., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.002 · Cited by 176
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 175
The relationship between the nucleolus and cancer: Current evidence and emerging paradigms
Oršolić, I., Jurada, D., Pullen, N., Oren, M., Eliopoulos, A. G., & Volarević, S. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.12.004 · Cited by 170
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.012 · Cited by 162
Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues
Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-03-657379 · Cited by 158
Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis
Bursać, S., Brdovčak, M. C., Donati, G., & Volarević, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.014 · Cited by 166
Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 156
Clonal evolution in myelodysplastic syndromes
da Silva-Coelho, P., Kroeze, L. I., Yoshida, K., Koorenhof‐Scheele, T. N., Knops, R., van de Locht, L. T., de Graaf, A. O., Massop, M., Sandmann, S., Dugas, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15099 · Cited by 158
How we treat lower-risk myelodysplastic syndromes
Fenaux, P., & Adès, L. (2013) · Blood · doi:10.1182/blood-2013-02-453068 · Cited by 150
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A. G., Göhring, G., Giagounidis, A. A. N., Selleslag, D., Muus, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.098103 · Cited by 139
Self-citation
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124
Clinical Implications of Clonal Hematopoiesis
Steensma, D. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.002 · Cited by 126
The molecular pathogenesis of the myelodysplastic syndromes
Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 120
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 111
Mutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 108
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
Wei, S., Chen, X., McGraw, K. L., Zhang, L., Komrokji, R. S., Clark, J., Cáceres, G., Billingsley, D., Sokol, L., Lancet, J. E., et al. (2012) · Oncogene · doi:10.1038/onc.2012.139 · Cited by 109
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Bejar, R. L. (2014) · Haematologica · doi:10.3324/haematol.2013.085217 · Cited by 107
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Takahashi, K., Patel, K. P., Bueso-Ramos, C., Zhang, J., Gumbs, C. E., Jabbour, E. J., Kadia, T. M., Andreff, M., Konopleva, M. Y., Dinardo, C. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7290 · Cited by 103
How we manage adults with myelodysplastic syndrome
Fenaux, P., Platzbecker, U., & Adès, L. (2019) · British Journal of Haematology · doi:10.1111/bjh.16206 · Cited by 103
Guidelines for the diagnosis and management of adult myelodysplastic syndromes
Killick, S. B., Carter, C., Culligan, D. J., Dalley, C. D., Das-Gupta, E. P., Drummond, M. W., Enright, H., Jones, G. L., Kell, J., Mills, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12694 · Cited by 97
Self-citation
Translation factors and ribosomal proteins control tumor onset and progression: how?
Loreni, F., Mancino, M., & Biffo, S. (2013) · Oncogene · doi:10.1038/onc.2013.153 · Cited by 91
Myelodysplastic syndromes
Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96
Current therapy of myelodysplastic syndromes
Zeidan, A. M., Linhares, Y. P. L., & Gore, S. D. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.003 · Cited by 87
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
Mallo, M., Rey, M. D., Ibáñez, M., Calasanz, M. J., Arenillas, L., Larráyoz, M. J., Pedro, C., Jerez, A., Maciejewski, J. P., Costa, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12354 · Cited by 89
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes
Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4127 · Cited by 83
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia
Kar, S. A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M. G., Guinta, K. M., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.064048 · Cited by 88
Myelodysplastic Syndrome Updated
Hasserjian, R. P. (2018) · Pathobiology · doi:10.1159/000489702 · Cited by 81
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion
Sebaa, A., Adès, L., Baran‐Marszak, F., Mozziconacci, J., Penther, D., Dobbelstein, S., Stamatoullas, A., Récher, C., Prébet, T., Moulessehoul, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21993 · Cited by 81
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
on behalf of the International Working Group on MDS with del(5q), Kuendgen, A., Lauseker, M., List, A. F., Fenaux, P., Giagounidis, A. A. N., Brandenburg, N. A., Backstrom, J. T., Glasmacher, A., Hasford, J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.369 · Cited by 81
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome
Mian, S. A., Smith, A., Kulasekararaj, A. G., Kizilors, A., Mohamedali, A. M., Lea, N. C., Mitsopoulos, C., Ford, K., Nasser, E. E., Seidl, T., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.075325 · Cited by 77
Self-citation
Clonal Heterogeneity As Detected by Metaphase Karyotyping Is an Indicator of Poor Prognosis in Acute Myeloid Leukemia
Bochtler, T., Stölzel, F., Heilig, C. E., Kunz, C., Mohr, B., Jauch, A. S., Janssen, J. W. G., Krämer, M., Benner, A., Bornhäuser, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7921 · Cited by 76
The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
Hong, M., & He, G. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0002 · Cited by 83
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease
Visconte, V., Tiu, R. V., & Rogers, H. J. (2014) · Blood Research · doi:10.5045/br.2014.49.4.216 · Cited by 73
Consequences of mutant TET2 on clonality and subclonal hierarchy
Hirsch, C. M., Nazha, A., Kneen, K. E., Abazeed, M. E., Meggendorfer, M., Przychodzen, B. P., Nadarajah, N., Ademà, V., Nagata, Y., Goyal, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0150-9 · Cited by 71
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
Mossner, M., Jann, J.-C., Nowak, D., Platzbecker, U., Giagounidis, A. A. N., Götze, K. S. S., Letsch, A., Haase, D. T., Shirneshan, K., Braulke, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.111 · Cited by 68
The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications
Zhang, L., McGraw, K. L., Sallman, D. A., & List, A. F. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1266625 · Cited by 67
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
Müller‐Thomas, C., Rudelius, M., Rondak, I., Haferlach, T., Schanz, J., Huberle, C., Schmidt, B., Blaser, R., Kremer, M., Peschel, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.104760 · Cited by 67
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms
Loghavi, S., Kanagal‐Shamanna, R., Khoury, J. D., Medeiros, L. J., Naresh, K. N., Nejati, R., & Patnaik, M. M. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100397 · Cited by 69
Next‐generation sequencing – feasibility and practicality in haematology
Kohlmann, A., Großmann, V., Nadarajah, N., & Haferlach, T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12194 · Cited by 65
Ribosome biogenesis and cancer: basic and translational challenges
Bustelo, X. R., & Dosil, M. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.003 · Cited by 65
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
Gaymes, T. J., Mohamedali, A. M., Patterson, M., Matto, N., Smith, A., Kulasekararaj, A. G., Chelliah, R., Curtin, N. J., Farzaneh, F., Shall, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.079251 · Cited by 64
Self-citation
Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome
Volkert, S., Kohlmann, A., Schnittger, S., Kern, W., Haferlach, T., & Haferlach, C. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22151 · Cited by 63
Myelodysplastic Syndromes
Germing, U., Kobbe, G., Haas, R. R., & Gattermann, N. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0783 · Cited by 67
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
Falini, B., & Martelli, M. P. (2023) · American Journal of Hematology · doi:10.1002/ajh.26812 · Cited by 62
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes
Hsu, J., Reilly, A., Hayes, B. J., Clough, C. A., Konnick, E. Q., Torok‐Storb, B., Gülsüner, S., Wu, D., Becker, P. S., Keel, S., et al. (2019) · Blood · doi:10.1182/blood.2018884338 · Cited by 63
Clinical decision-making and treatment of myelodysplastic syndromes
Hellström‐Lindberg, E., & Kröger, N. M. (2023) · Blood · doi:10.1182/blood.2023020079 · Cited by 61
Self-citation
Integration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet?
Kohlmann, A., Grossmann, V., & Haferlach, T. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.008 · Cited by 57
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
Beličková, M., Veselá, J., Jonasova, A. T., Pejsova, B., Votavová, H., Merkerová, M. D., Zemanová, Z., Březinová, J., Mikulenková, D., Lauermannová, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9200 · Cited by 56
Targeting cereblon in hematologic malignancies
Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55
Genetics of Myelodysplastic Syndromes: New Insights
Graubert, T. A., & Walter, M. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.543 · Cited by 56
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms
Martinez-Aviles, L. M., Besses, C., Álvarez‐Larrán, A., Torres, E., Serrano, S., & Bellosillo, B. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1330-0 · Cited by 56
Myelodysplastic Syndromes, Version 2.2015
Greenberg, P. L., Stone, R. M., Bejar, R. L., Bennett, J. M., Bloomfield, C. D., Borate, U., de Castro, C. M., Deeg, H. J., Dezern, A. E., Fathi, A. T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0038 · Cited by 56
Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 54
Anemia as the Main Manifestation of Myelodysplastic Syndromes
Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Lodé, L., Ménard, A., Flet, L., Richebourg, S., Loirat, M., Eveillard, M., Le Bris, Y., Godon, C., Theisen, O., Gagez, A.-L., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181404 · Cited by 52
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients
Cáceres, G., McGraw, K. L., Yip, B. H., Pellagatti, A., Johnson, J., Zhang, L., Liu, K., Zhang, L. M., Fulp, W. J., Lee, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311055110 · Cited by 57
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
on behalf of the German MDS Study Group, Platzbecker, U., Braulke, F., Kündgen, A., Götze, K. S. S., Bug, G., Schönefeldt, C., Shirneshan, K., Röllig, C., Bornhäuser, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.26 · Cited by 53
Deletion 5q MDS: Molecular and therapeutic implications
Komrokji, R. S., Padron, E., Ebert, B. L., & List, A. F. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.10.013 · Cited by 54
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
Grossmann, V., Roller, A., Klein, H., Weißmann, S., Kern, W., Haferlach, C., Dugas, M., Haferlach, T., Schnittger, S., & Kohlmann, A. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.003 · Cited by 52

Authors: Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellström-Lindberg, E., & Mufti, G. J.
Affiliations: King's College London (GB)
From the Department of Medicine, Center for Experimental Hematology, and Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden; King's College London School of Medicine, London, United Kingdom; and Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
ORCID: Jädersten, Martin
Saft, Leonie
Smith, Alexander
Kulasekararaj, Austin
Göhring, Gudrun
Schlegelberger, Brigitte
Mufti, Ghulam J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-05-20
Volume: 29
Issue: 15
Pages: 1971-1979
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2010.31.8576
OpenAlex: W2131256397
Cited by: 463
References: 33
Citations by year: 2026: 10 · 2025: 12 · 2024: 26 · 2023: 23 · 2022: 27 · 2021: 31 · 2020: 27 · 2019: 33 · 2018: 28 · 2017: 37 · 2016: 34 · 2015: 44 · 2014: 38 · 2013: 47 · 2012: 26
FWCI: 28.44
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords: TP53 mutation, myelodysplastic syndrome, del(5q), p53 expression, disease progression, cytogenetic response, clone size, disease heterogeneity
MeSH terms: Adult, Aged, Aged, 80 and over, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Peptide Fragments, Prognosis, Risk, Leukemia, Myeloid, Acute, Genes, p53, Tumor Suppressor Protein p53, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks